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Abstract 
Introduction: Mycophenolate mofetil (MMF) or enteric coated mycophenolate sodium (EC-
MPS) and steroids are used for induction and maintenance therapy in severe lupus nephritis 
(LN). Blood concentrations of mycophenolic acid (MPA), the active metabolite of these 
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drugs varies among LN patients. The objective of this study was to examine whether 
concentration controlled (CC) dosing (via therapeutic drug monitoring) of EC-MPS result in 
a higher proportion of participants achieving target exposure of MPA compared to fixed 
dosing (FD). An additional aim of the study was to evaluate the influence of CC dosing on 
clinical outcomes.  
Methods: Nineteen participants were randomly assigned either to FD or CC group. All the 
participants were eligible to have free and total measurements of MPA over a period of 8-12 
hours on three different occasions. Area under the concentration-time curve between 0 and 12 
hours (AUC0-12) was calculated using non-compartmental method. Dose of EC-MPS was 
titrated according to AUC0-12 in the CC group.  
Results: Thirty-two AUC0-12 measurements were obtained from 9 FD and 9 CC participants. 
Large interpatient variability was observed in both groups but was more pronounced in FD 
group. There were no significant differences between FD and CC participants in any 
pharmacokinetic parameters across the study visits except for total C0 (FD 2.0 ± 0.3 mg/L vs. 
CC 1.1 ± 0.3; p = 0.01) and dose-normalised C0 (FD 2.9 ± 0.2 mg/L/g vs. CC 2.1 ± 0.7 
mg/L/g; p = 0.04) at the second visit and total AUC0-12 (FD 66.6 ± 6.0 mg·h/L vs. CC 35.2 ± 
11.4 mg·h/L; p = 0.03) at the third visit. At the first study visit, 33.3% of the FD and 11.1% 
of the CC participants achieved the target AUC (p = 0.58). From the second visit, none of the 
FD participants, compared to all the CC participants, achieved target AUC0-12 (p = 0.01). 
More CC participants achieved remission compared to FD participants (absolute difference of 
-22.2, 95% confidence interval −0.19-0.55; p = 0.62). The mean free MPA AUC0-12 was 
significantly lower in those who had complete remission. 
Conclusions: CC participants reached target AUC0-12 quicker. Larger studies are required to 
test clinical efficacy. 
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Introduction 
Regional and international guidelines are available for the management of lupus nephritis 
(LN) for both adult and paediatric populations.1-5 These guidelines advocate steroids and 
mycophenolic acid (MPA) prodrugs, mycophenolate mofetil (MMF) or enteric coated 
mycophenolate sodium (EC-MPS) for induction and maintenance therapy in class III, IV and 
V LN.3 Guidelines recommend gradual dose titration of MMF to 2000-3000 mg/day as 
induction therapy and 1000-2000 mg/day as maintenance treatment to achieve best possible 
toxicity/efficacy ratio.3 An equivalent dose of EC-MPS at 1440-2160 mg is administered as 
induction therapy.6 The dose of MMF varies in clinical studies and this partly accounts for 
variable efficacy. Further, adverse events lead to dose reduction and suboptimal outcome.7 
Therapeutic drug monitoring (TDM) is used to maximise the efficacy and minimise the side 
effects with therapy based on exposure rather than dose.8 It is unclear if the TDM of MPA, 
the active entity and dose modulation of its prodrugs (MMF/EC-MPS) would improve 
outcome in LN patients. While some studies have shown that area under the concentration-
time curve (AUC) of 35-45 mg·h/L of MPA is associated with remission and therapeutic 
efficacy, there are no randomised controlled trials.9-13 Administration of 1000 mg of MMF 
and equivalent 720 mg of EC-MPS result in a similar 12-hour MPA AUC,6 though the 
pharmacokinetic profiles of MMF and EC-MPS differ. There are limited data on 
concentration-controlled EC-MPS dosing (via TDM) in LN patients. Additionally, there are 
no data on free MPA pharmacokinetics and relationship to outcome in LN patients treated 
with EC-MPS. This is important in LN patients with hypoalbuminemia as MPA is highly 
protein bound and the unbound drug is responsible for pharmacological effect. We therefore 
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performed a randomised controlled trial to determine whether concentration-controlled (CC) 
dosing of EC-MPS via TDM results in a higher proportion of participants achieving target 
MPA exposure range in LN compared with fixed-dosing (FD). We also report on the efficacy 
of EC-MPS in both groups and free MPA exposure on their clinical outcome. 
 
Materials and Method 
The protocol of POEMSLUN has previously been published.14  
ETHICAL CONSIDERATIONS 
The Human Research Ethics Committee of the Royal Brisbane and Women’s Hospital 
(RBWH) (HREC/10/QRBW/426) approved this study. The study was registered on the 
Australia New Zealand Clinical Trial Registry ACTRN12611000798965. 
PARTICIPANTS 
The participants who fulfil the inclusion and exclusion criteria were recruited from in-patients 
at RBWH Renal and Rheumatology Departments or patients attending the Renal 
Rheumatology Lupus Vasculitis Clinic. All participants who had biopsy proven Class 
III/IV/V LN and aged ≥18 years and received EC-MPS for more than two weeks either as 
induction or maintenance therapy were eligible for recruitment. All consenting participants 
were randomized to CC or FD group. The participants were stratified to induction and 
maintenance phase of treatment with EC-MPS.  
RANDOMIZATION  
Participants were block randomized into Group 1 or 2 in permuted block sizes of 2 and 4 with 
33 and 66 percent respectively; stratified for induction and maintenance therapy. Due to the 
nature of intervention, research staff except the laboratory bio-analysts and participants, were 
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not masked to the treatment allocation. The participants were followed up for 12 months after 
the last participant was recruited. 
 
STUDY INTERVENTION 
Group 1: Fixed-dosing (FD) 
Oral EC-MPS 30 mg/kg body weight was administered to induce remission. EC-MPS dosage 
was reduced by 180 mg twice daily on achieving complete remission or if there were side 
effects or if the total white cell count was <3500/mm3. 
Group 2: Concentration-controlled (CC)  
The oral EC-MPS dose was titrated according to the AUC0-12; tested at the first visit and 
adjusted to a target AUC0-12 of 40 to 60 mg·h/L at the second visit. The dosage was reduced 
if the AUC0-12 was above 60 mg·h/L. Once there was remission or if participants were 
randomized at maintenance phase of treatment, the AUC0-12 of 30 to 50 mg·h/L was 
maintained. Both groups received similar management other than EC-MPS dosing.  
DATA COLLECTION  
At the time of entry to study, clinical and demographic data were collected for each 
participant, including age, gender, weight, height, allergies, clinical information, other co-
morbidities and concomitantly prescribed drugs. Laboratory investigations were performed 
every 12 weeks consisting of urine sediment examination, 24-hour urinary protein 
measurement and/ or urine protein to creatinine ratio (uPCR), renal function assessments-
eGFR, liver function tests, complement components C3 and C4, antinuclear antibody (ANA), 
anti–double stranded DNA antibody and pharmacokinetic analysis of MPA. 
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PHARMACOKINETIC SAMPLING 
Pharmacokinetic analysis of MPA was performed at different time points. Participants who 
entered the study at induction phase had their first analysis at 1-2 months, the second at 3-4 
months and the third at 7-9 months. Protocol was amended and the participants in the 
maintenance phase had their assays at the time of entry and the second at three months later. 
Where participants were unable to attend for a 12-hour AUC determination, we extrapolated 
AUC0-12 from an 8-hour AUC determination as has been used elsewhere.14 Blood samples 
were collected pre and post EC-MPS dose at 15-time points for the 8-hour group and, where 
participant consented, 17 samples for the 12-hour group. The pharmacokinetic values were 
calculated using non-compartmental methods. The AUC0-12 was calculated using the 
trapezoidal rule.  
BIOANALYSIS 
Total plasma MPA concentrations were determined using a validated ultra-high performance 
liquid chromatography- tandem mass spectrometry (UHPLC-MS/MS) method.  MPA-d3 
internal standard (Toronto Research Chemicals, Toronto, ON, Canada) in methanol was 
added to plasma, vortexed and centrifuged prior to analysis by UHPLC using an Acquity 
UPLC HSS T3 C18 analytical column (1.8 µm, 2.1 x 100 mm) and Acquity BEH C18 pre-
column (1.7 µm, VanGuard 2.1 5 mm) (Water Corporation, Milford, MA, USA) maintained 
at 40 °C, with gradient elution using 2mM ammonium acetate and 0.1% formic acid in water 
(mobile phase A) and 2mM ammonium acetate and 0.1% formic acid in methanol (mobile 
phase B). Multiple reaction monitoring was carried out using positive electrospray ionization 
and detection of MPA (321.2>207.2) and MPA-d3 (324.3>310.2 transitions (Water 
Corporation, Milford, MA, USA). 
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Ultrafiltrates of plasma free mycophenolate were prepared by equilibrating 500µL of plasma 
at 37 ºC for 30 minutes in Centrifree regenerated cellulose 30,000 molecular weight cut-off 
centrifugal filter devices (Merck Millipore, Cork, Ireland) before centrifugation at 3040×g for 
20 minutes at 37 ºC. The ultrafiltrate was then transferred to autosampler vials, mixed with 
MPA-d3 internal standard and injected directly into the UHPLC-MS/MS system described 
above. The assay was linear between 0.1-60 mg/L with intra-assay imprecision < 4% and 
inter-assay imprecision < 9%.  
 
OUTCOME MEASURES 
Primary 
TDM of MPA was measured in CC and FD group to determine whether TDM-guided dosing 
of EC-MPS resulted in achieving established targets of MPA AUC0-12 of 40 to 60 mg·h/L in 
participants receiving induction therapy and target AUC0-12 of 30 to 50 mg·h/L in participants 
receiving maintenance therapy compared to the standard empirical dosing in participants with 
LN.  
Secondary 
Secondary outcome measures were complete and partial remission rates in the induction 
group and sustained remission/renal relapse in the maintenance group.  
Complete remission was defined as a decrease in urinary protein measured over 24 hours to 
less than 500 mg/24 h, uPCR less than 0.5 mg/mg (50 mmol/mg), normal serum albumin and 
stabilisation (± 25%) or improvement in serum creatinine levels at week 24 from the initial 
sample.5 Partial remission was defined as stabilisation (± 25%) or improved renal function 
(but still not to normal) with reduction of proteinuria by more than 50% ranging between 300 
to 3000mg/24h and a serum albumin of more than 30 g/L.5 Renal relapse was defined as 
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“recrudescence of renal disease after an initial response demonstrated by a recent increase in 
serum creatinine by >50% with active urinary sediment and or increase in proteinuria to 3500 
mg/day or greater”.15 Proteinuria was measured using uPCR or by 24-hour urinary protein 
excretion.  
Statistical methods 
An interim analysis demonstrated slow recruitment and the trial was terminated as most 
patients in the CC group achieved target AUC before intervention. Continuous data were 
compared using the Student t-test or Mann-Whitney U test as appropriate and dichotomous 
variables were compared using the Pearson’s chi-square or Fisher’s exact test as appropriate. 
Correlations between individual MPA concentrations and AUC0-12 for total and free drug 
concentrations were evaluated by Pearson or Spearman correlation as appropriate. All data 
were analysed on an intention-to-treat basis, and a significance level of 0.05 was assumed. 
One of the coauthor, MHAA, who was masked to the study allocation and not involved in the 
clinical care of the participants adjudicated outcome measures.  
 
Results 
BASELINE DEMOGRAPHICS AND CLINICAL CHARACTERISTICS 
Twenty-seven patients were screened for eligibility, of whom 19 were randomly assigned to 
the FD (n = 9) or CC (n = 10) treatment groups. One participant was not compliant with 
treatment and was excluded from outcomes assessment. The final analysis only included 18 
participants; nine participants in each treatment group (Figure 1). 
The baseline characteristics of the 18 participants are presented in Table 1. There were no 
significant differences between FD and CC participants in any demographic and clinical 
characteristics at study entry. The mean (SD) follow-up time was 82.2 ± 33.3 weeks. 
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MYCOPHENOLIC ACID PHARMACOKINETICS 
The total and free MPA pharmacokinetic parameters are summarised in Table 2. Thirty-two 
AUC0-12 measurements were obtained from 18 participants; 18 AUCs from the first visit, 9 
from the second visit and 5 from the third visit. Large inter-patient variability (percentage 
coefficient of variation (%CV) of ≥40%) was observed in all pharmacokinetic parameters 
across both groups but these variations were more pronounced in the FD treatment group 
(%CV of ≥60%). Correlations between MPA concentrations at different sampling time-
points, with AUC0-12 for total and free MPA are presented in Table 3. A moderate positive 
correlation was observed between MPA AUC0-12 and C0, Cmax and C12 for total and free MPA 
concentrations (Figure 2). Serum albumin inversely correlated with free C12 (r = –0.42; p = 
0.04) and free MPA AUC0-12 (r = –0.43; p = 0.03). There were no significant differences 
between FD and CC participants in any pharmacokinetic parameters across the study visits 
except for total C0 (FD 2.0 ± 0.3 mg/L vs. CC 1.1 ± 0.3; p = 0.01) and dose-normalised C0 
(FD 2.9 ± 0.2 mg/L/g vs. CC 2.1 ± 0.7 mg/L/g; p = 0.04) at the second visit and total AUC0-12 
(FD 66.6 ± 6.0 mg·h/L vs. CC 35.2 ± 11.4 mg·h/L; p = 0.03) at the third visit (Table 2).  
PRIMARY OUTCOME 
The MPA exposure between FD and CC treatment groups across the three study visits is 
presented in Table 3 and Figure 3. Overall, 20.0% (n = 3/15) of FD participants and 52.9% (n 
= 9/17) of CC participants achieved the target MPA exposure range (p = 0.06). At the first 
study visit (week 4–6), only 33.3% (n = 3/9) of the FD participants and 11.1% (n = 1/9) of 
the CC participants achieved the target MPA exposure range (p = 0.58). However, from week 
14, none of the FD participants achieved the target MPA exposure whilst all the CC 
participants did. Nevertheless, a statistically significant difference between the two treatment 
groups was only observed on the second study visit (week 14-16) (FD 0.0% [n = 0/4] vs. CC 
100.0% [n = 5/5]; p = 0.01). Among those who failed to achieve the target exposure range 
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(Figure 4), 75% (n = 9/12) of the FD participants demonstrated supra-therapeutic MPA 
exposure (mean ± SD [range] MPA exposure 57.9 ± 36.5 [1-126.3] mg·h/L). 
SECONDARY OUTCOMES 
Table 4 presents the differences in participant characteristics between those who 
demonstrated complete remission/sustained remission and partial remission in this study. At 
24 weeks, 7 of the 9 FD participants (77.8%) and 5 of the 9 CC participants (55.6%) 
demonstrated either complete remission in the induction group or sustained remission in the 
maintenance group (absolute difference of −22.2, 95% confidence interval −0.19-0.55; p = 
0.62). In this study, no participants had renal relapse in the maintenance group. There was no 
significant difference in the mean total MPA AUC0-12 among participants who demonstrated 
complete and partial remission (37.8 ± 18.9 mg·h/L vs. 49.6 ± 41.7 mg·h/L; p = 0.32). 
However, the mean free MPA AUC0-12 was significantly lower in those who had complete 
remission than those with partial remission (311.6 ± 143.0 µg·h/L vs. 631.8 ± 332.8 µg·h/L; p 
= 0.01). In this study, clinical response was not significantly associated with the achievement 
of target MPA exposure (Table 4). 
Serum creatinine, blood urea, estimated glomerular filtration rate, serum albumin, serum C3 
and C4 were similar between FD and CC participants throughout the 48-week study period 
(Figure 5).     
ADVERSE EVENTS 
The total number of adverse events were similar between FD and CC treatment groups (Table 
5). Nausea and vomiting as well as fever occurred in 2 patients for each group. The median 
(IQR) total MPA exposure of those participants with and without adverse events were 27.3 
mg/L and 39.2 mg/L (p = 0.11), respectively. The median (IQR) free MPA exposure of 
participants with and without adverse events were 553.9 µg/L and 338.0 µg/L, respectively (p 
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= 0.404). Two participants in each treatment group had to discontinue EC-MPS due to 
treatment-related adverse events. 
 
Discussion 
Our study is the first randomised controlled trial in LN patients to determine if TDM adjusted 
dosing achieved established MPA exposure targets efficiently compared to FD of EC-MPS. 
All CC participants reached target MPA exposure earlier than the FD group. The difference 
was statistically significant at the second study visit as EC-MPS dose was adjusted based on 
MPA exposure during the first visit. 
The objective of CC dosing is to improve the clinical outcome and reduce adverse events 
with adequate drug exposure. Mycophenolate Mofetil and EC-MPS are typically 
administered at a FD in patients with LN. There is wide interpatient variability of blood 
concentrations of MPA, the active metabolite of MMF and EC-MPS. There are several 
studies on MMF dosing based on TDM attempting to improve outcome in LN but there is 
little data on EC-MPS. Neuman et al. were the first to show that the MPA exposure from EC-
MPS is comparable in 12 autoimmune patients (mean 27.3 ± 17.4 mg/L) and 11 renal 
transplant patients (mean 19.6 ± 15.7 mg/l).16 Lertdurrongluk et al. studied the 
pharmacokinetics of MPA in 18 Thai patients with biopsy-proven LN, a month after initiating 
treatment with a FD of 1.0-1.5 g/D of MMF in 12 and 1080-1440 mg/D of EC-MPS in 6 
patients respectively.11 The responders had a significantly higher MPA AUC (>45mg·h/L). 
All these studies were either observational or retrospective and the pharmacokinetics of MPA 
was studied after administering FD of MPA prodrugs. 
A large inter-patient variability was observed in all pharmacokinetic parameters across both 
the groups as in other studies; however, this was more pronounced in the FD group. We 
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observed a moderate correlation between MPA AUC0-12 with C0 and Cmax for total and free 
MPA and a stronger correlation between MPA AUC0-12 and C12 total and free MPA 
concentrations in contrast to the lack of correlation reported by Lertdumrongluk et al.11 
Djabarouti et al. studied TDM in 35 Systemic Lupus Erythematosus patients with no renal 
involvement, 21 receiving MMF and 14 taking EC-MPS.17 They concluded, as we observed 
in our study with EC-MPS, that C12 after MMF ingestion could predict MPA AUC0-12. 
They
 
however found the correlation to be weak in patients receiving EC-MPS. 
We have shown earlier attainment of target AUC with lower doses using CC dosing in LN as 
compared with FD. This may be of importance with limiting side-effects in the longer term, 
especially in patients with history of past immunosuppression or immune impairment and in 
regions where LN is more resistant to therapy. More CC participants achieved remission with 
lower doses compared to FD participants although this difference did not reach statistical 
significance. 
This is the first report to study the free MPA concentration on clinical outcome in LN patients 
treated with EC-MPS. Abd Rahman et al. studied the unbound fraction of MPA and its 
metabolite 7 -O-MPA-β-glucuronide (MPAG) in 25 LN patients receiving MMF.18 They 
found similar MPA exposure between responders and non-responders. Our study also showed 
higher free MPA exposure in patients who had partial remission. Patients who had partial 
remission had lower albumin resulting in higher free MPA exposure. We found an inverse 
correlation of albumin to MPA exposure in LN patients receiving EC-MPS. 
This study has limitations with small sample size and premature termination due to slow 
recruitment. Despite these limitations, we observed that therapeutic exposure of MPA could 
be achieved with CC dosing. A larger study would define if CC dosing of EC-MPS improves 
therapeutic outcome in LN patients.  
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Conclusions 
Concentration-controlled dosing of EC-MPS resulted in a higher proportion of participants 
achieving target exposure of MPA quicker. Larger prospective studies on CC drug dosing and 
therapeutic outcome will likely demonstrate the clinical efficacy of this approach. 
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Figure Legend 
Figure 1: Study flow chart 
Figure 2: Correlations between MPA C0 and MPA AUC0-12 for (A) total MPA and (B) free 
MPA concentrations, between MPA Cmax and AUC0-12 for (C) total MPA and (D) free 
MPA concentrations, and between MPA C12 and MPA AUC0-12 for (D) total MPA and (E) 
free MPA concentrations 
Figure 3: Total and free MPA AUC0-12 between fixed-dosing and concentration-controlled 
participants across the study visits a,b 
Figure 4: MPA exposure between fixed-dosing and concentration-controlled participants 
across the study visits a,b,c 
Figure 5: Changes in treatment-related variables over the 48-week of study period 
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Table 1: Baseline demography and clinical characteristics of the study population a 
 Fixed–dosing (n = 9) Concentration–controlled (n = 9) p–valueb 
Age (in years) 47.6 ± 16.0 50.9 ± 14.0 0.64 
Gender, n (%)    
   Male 2 (22.2) 2 (22.2) 1.00 
   Female 7 (77.8) 7 (77.8)  
Race, n (%)    
   Caucasian 8 (88.9) 7 (77.8) 0.38 
   Asian 0 (0.0) 1 (11.1)  
   Hispanic 0 (0.0) 1 (11.1)  
   Other 1 (11.1) 0 (0.0)  
Weight (kg) 75.5 ± 14.2 81.0 ± 24.2 0.57 
Renal pathology, n (%)    
   ISN/RPS Class III 2 (22.2) 2 (22.2) 1.00 
   ISN/RPS Class IV 5 (55.6) 5 (55.6)  
   ISN/RPS Class V 2 (22.2) 2 (22.2)  
Serum creatinine (µmol/L) 99.9 ± 40.7 83.9 ± 42.8 0.43 
eGFR (mL/min/1.73 m2) 67.3 ± 25.0 88.1 ± 39 0.20 
eGFR classification, n (%)    
Urine protein (g/24 hours) 1.4 ± 1.5 2.9 ±3.8 0.39 
Urine protein/creatinine ratio 38.0 (10.5 – 174.0) 18.0 (6.5 – 557.5) 0.80 
Serum albumin (g/L) 36.4 ± 5.6 34.0 ± 8.9 0.50 
Serum complement (g/L)    
   C3 0.8 ± 0.3 1.0 ± 0.4 0.36 
   C4 0.2 ± 0.1 0.2 ± 0.1 0.94 
Anti–dsDNA 33.0 ± 24.8 48.1 ± 38.6 0.46 
EC–MPS dose (g/day) 1.44 (0.45 – 1.44) 1.44 (0.54 – 1.44)  0.78 
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EC–MPS dose (g/kg/day) 0.01 (0.01 – 0.02)  0.02 (0.01 – 0.03)  0.67 
Prednisolone dose (mg/day) 10.0 (5.0 – 15.0)  8.0 (5.0 – 40.0)  0.86 
ALP = alkaline phosphatase; ALT = alanine transaminase; Anti–dsDNA = anti–double strand DNA; ARB = angiotensin II receptor blocker; 
AST = aspartate transaminase; BMI = body mass index; EC–MPS = enteric–coated mycophenolate sodium; eGFR = estimated glomerular 
filtration rate; GGT = gamma–glutamyl transferase; ISN/RPS = International Society of Nephrology/Renal Pathology Society 
aData are presented as mean ± standard deviation or median (interquartile range) for continuous variables and number and percentage for 
categorical variables. 
bContinuous variables were compared using the t–test or Mann–Whitney U–test as appropriate and dichotomous variables were compared using 
the Pearson’s chi–square test or Fisher’s exact test as appropriate. 
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Table 2: Summary of pharmacokinetic sampling and pharmacokinetic parameters of total and free mycophenolic acid in the study populationa 
Total number of MPA AUCs 32 
Number of MPA AUCs per study visit, n (%)  
   First visitb 18 (56.3) 
   Second visitc 9 (28.1) 
   Third visitd 5 (15.6) 
 
 First visit Second visit Third visit 
Total MPA 
concentration 
FD 
n = 9 
CC 
n = 9 
pe FD 
n = 4 
CC 
n = 5 
pe FD 
n = 2 
CC 
n = 3 
pe 
 AUC0-12 (mg·h/L) 49.0 ± 35.5 29.0 ± 16.6 0.15 62.4 ± 39.4 35.0 ± 3.9 0.26 66.6 ± 6.0 35.2 ± 11.4 0.03 
 Dose normalised  
 AUC0-12 (mg·h/L/g) 
117.9 ± 94.1 45.5 ± 27.1 0.05 92.9 ± 54.3 62.1 ± 6.3 0.34 92.5 ± 8.2 75.2 ± 17.4 0.37 
 C0 (mg/L) 1.8 ± 1.3 1.2 ± 0.2 0.30 2.0 ± 0.3 1.1 ± 0.3 0.01 2.0 ± 0.0  2.7 ± 0.5 0.31 
 Dose normalised C0  
 
(mg/L/g) 
4.6 ± 3.9 2.2 ± 1.5 0.14 2.9 ± 0.2 2.1 ± 0.7 0.04 2.8 ± 0.0 5.1 ± 1.2 0.23 
 Cmax (mg/L) 15.5 ± 6.6 11.1 ± 7.1 0.20 23.4 ± 15.1 16.5 ± 6.3 0.44 17.0 ± 4.1 14.5 ± 15.1 0.86 
 Dose normalised  
 Cmax (mg/L/g) 
43.5 ± 39.8 15.3 ± 8.4 0.08 35.4 ± 21.9 29.2 ± 11.5 0.64 23.6 ± 5.7 27.1± 27.6 0.88 
 C12 (mg/L) 2.7 ± 2.2 1.4 ± 0.6 0.13 2.6 ± 1.3 1.4 ± 0.5 0.14 2.9 ± 1.3 2.4 ± 0.8 0.70 
 Dose normalised C12  
 
(mg/L/g) 
6.9 ± 5.8 2.2 ± 1.0 0.06 3.8 ± 1.6 2.6 ± 1.0 0.25 4.0 ± 1.8 4.7 ± 1.9 0.76 
 Tmax (h) 3.9 ± 2.3 3.7 ± 1.8 0.79 3.5 ± 1.4 4.0 ± 2.0 0.70 4.0 ± 4.2 3.3 ± 1.1 0.85 
 First visit Second visit Third visit 
Free MPA 
concentration 
FD 
n = 9 
CC 
n = 9 
pe FD 
n = 4 
CC 
n = 5 
pe FD 
n = 2 
CC 
n = 3 
pe 
 AUC0-12 (µg·h/L) 302.6  266.2  0.37 484.0  323.0  0.40 453.8  288.3  0.67 
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(284.4 – 574.2) (138.9 – 506.7) (414.6 – 736.4) (179.8 – 509.1) (367.3 – 540.3) (186.9 – 389.7) 
 Dose normalised  
 AUC0-12 (µg·h/L/g) 
1431.1  
(396.3 – 1595.0) 
460.2  
(324.1 – 1000) 
0.14 672.3  
(655.7 – 1022.7) 
625.8  
(333.0 – 956.6) 
0.63 630.3  
(510.2 – 750.4) 
547.7 
(373.8 – 721.7) 
0.67 
 C0 (µg/L) 10.1  
(7.3 – 20.5) 
11.9  
(10.3 – 18.3) 
0.63 12.5  
(11.4 – 12.9) 
6.2  
(4.6 – 10.9) 
0.11 16.9  
(10.6 – 23.3) 
18.5  
(14.3 – 22.6)  
1.00 
 Dose normalised C0  
 
(µg/L/g) 
32.1 ± 19.7 26.6 ± 10.7 0.53 18.3  
(17.8 – 18.8) 
11.4  
(8.6 – 21.5) 
0.40 23.5  
(14.7 – 32.4) 
35.8  
(26.5 – 45.2)  
1.00 
 Cmax (µg/L) 126.1  
(88.1 – 160.3) 
95.1  
(22.9 – 199.0) 
0.30 164.8  
(162.3 – 274.6) 
124.8  
(51.1 – 468.7)  
0.40 120.6  
(88.2 – 153.1) 
143.0  
(39.5 – 246.4) 
1.00 
 Dose normalised  
 Cmax (µg/L/g) 
351.4 ± 238.6 218.7 ± 207.2 0.30 305.1  
(263.6 – 419.6)  
242.3  
(94.6 – 873.66) 
0.86 167.6  
(122.5 – 212.6) 
267.6 
(79.0 – 456.3) 
1.00 
 C12 (µg/L) 15.1  
(8.5 – 20.5) 
10.5  
(9.2 – 25.8) 
0.73 13.2  
(11.8 – 21.9) 
6.2  
(4.6 – 17.6) 
0.23 16.9  
(10.6 – 23.3) 
16.6  
(10.5 – 22.6) 
0.67 
 Dose normalised C12  
 
(µg/L/g) 
47.3  
(14.0 – 94.4) 
19.8  
(18.0 – 41.5) 
0.53 19.2  
(18.8 – 30.8) 
11.4  
(8.6 – 34.9) 
0.23 23.5  
(14.7 – 32.3)  
35.8 
(26.5 – 45.2) 
1.00 
 Tmax (h) 3.3 ± 2.3 3.5 ± 1.8 0.84 2 (1.8 – 3) 5 (2 – 5.4) 0.40 4  
(1 – 7) 
3.5  
(2.5 – 4.5) 
1.00 
 Free  
 MPA AUC0-12/Total   
 MPA AUC0-12 (%) 
0.9 (0.5 – 1.0) 0.9 (0.6 – 1.2) 0.71 0.8 (0.7 – 0.8) 0.8 (0.8 – 1.5) 0.63 0.7 (0.6 – 0.8) 0.7 (0.7 – 0.8)  1.00 
 
AUC = area under the concentration-time curve; AUC0-12 = area under the concentration-time curve between 0 and 12 hours; C0 = pre-dose concentration 
before EC–MPS administration; C12 = trough concentration at 12 hours post-EC–MPS administration; Cmax = maximal MPA concentration; MPA = 
mycophenolic acid; Tmax = time when maximal MPA concentration is reached 
AC
CE
PT
ED
Copyright © 201 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of
Therapeutic DrugMonitoring and Clinical Toxicology
 9
aData are presented as mean ± standard deviation or median (interquartile range) for continuous variables and number and percentage for categorical 
variables. 
b4–6 weeks post–randomisation 
c14–16 weeks post–randomisation 
d28–32 weeks post–randomisation 
eVariables were compared using the t–test or Mann–Whitney U–test as appropriate and dichotomous variables were compared using the Pearson’s chi–
square test or Fisher’s exact test as appropriate. Bold values indicate statistical significance (p<0.05).
AC
CE
PT
ED
Copyright © 201 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of
Therapeutic DrugMonitoring and Clinical Toxicology
 9
 Table 3: Correlation between individual sampling time–point with total and free MPA AUC0–12    
Sampling time–point for total 
MPA concentration (h)  
Total MPA AUC0–12 (mg·h/L) 
(n = 32) 
Sampling time–point for free 
MPA concentration (h) 
Free MPA AUC0–12 (µg·h/L) 
(n = 24) 
 r
a p–value   ra p–value  
   C0 0.63 <0.001    C0 0.53 0.008 
   C1 0.63 0.004    C1 0.48 0.02 
   C1.5 0.63 <0.001    C1.5 0.58 0.006 
   C2 0.72 <0.001    C2 0.56 0.005 
   C2.5 0.68 <0.001    C2.5 0.60 0.002 
   C3 0.69 <0.001    C3 0.48 0.02 
   C3.5 0.63 <0.001    C3.5 0.58 0.003 
   C4 0.54 0.002    C4 0.47 0.02 
   C4.5 0.47 0.01    C4.5 0.49 0.02 
   C5 0.32 0.08    C5 0.36 0.08 
   C5.5 0.45 0.01    C5.5 0.47 0.02 
   C6 0.47 0.01    C6 0.56 0.006 
   C6.5 0.70 <0.001    C6.5 0.72 <0.001 
   C7 0.77 <0.001    C7 0.40 0.07 
   C8 0.88 <0.001    C8 0.72 <0.001 
   C10 0.72 0.009    C10 0.71 0.02 
   C12 0.60 <0.001    C12 0.63 0.001 
AUC0-12 = area under the concentration-time curve between 0 and 12 hours; MPA = mycophenolic acid 
aCorrelations between MPA concentrations and AUC0–12 were evaluated by Pearson or Spearman correlation as appropriate. 
bBold values indicate statistical significance (p<0.05)   
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Table 3: Achievement of target MPA exposure range between fixed–dosing and concentration–controlled participants stratified by 
study visit 
 Overall (n = 32) Study visit 
  1a 2b 3c 
Participants with therapeutic MPA exposure, n (%)d     
   Fixed–dosing 3 (20.0) 3 (33.3) 0 (0.0) 0 (0.0) 
   Concentration–controlled 9 (52.9) 1 (11.1) 5 (100.0) 3 (100.0) 
   p-valuee 0.06 0.58 0.01 0.10 
   Absolute difference (95% confidence interval) 0.32  
(-0.57 to 0.00) 
-0.22  
(-0.17 to 0.55) 
1.00  
(-1.00 to -0.34) 
1.00  
(-1.00 to -0.14) 
AUC0-12 = area under the concentration-time curve between 0 and 12 hours; MPA = mycophenolic acid 
aNumber of participants analysed (4–6 weeks post–randomisation): fixed–dosing = 9 and concentration–controlled = 9. 
bNumber of participants analysed (14–16 weeks post–randomisation): fixed–dosing = 4 and concentration–controlled = 5. 
cNumber of participants analysed (28–32 weeks post–randomisation): fixed–dosing = 2 and concentration-controlled = 3. 
dTarget MPA exposure for participants receiving EC–MPS as induction therapy was 40–60 mg·h/L and 30–50 mg·h/L for maintenance therapy. 
eComparisons were made using the Pearson’s chi–square test or Fisher’s exact test as appropriate. Bold values indicate statistical significance 
(p<0.05). AC
CE
TE
D
Copyright © 201 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of
Therapeutic DrugMonitoring and Clinical Toxicology
 9
Table 4: Differences in clinical characteristics and MPA pharmacokinetic parameters between participants who demonstrated partial 
and complete remission at week 24 post-randomisationa 
Variable Partial remission  
(n = 6) 
Complete remission  
(n = 12) 
p-valueb 
Age (in years) 46.1 ± 16.2 50.8 ± 14.3 0.55 
Gender, n (%)    
   Male 2 (33.3) 2 (16.7) 0.57 
   Female 4 (66.7) 10 (83.3)  
Race, n (%)    
   Caucasian 5 (83.3) 10 (83.3) 0.39 
   Asian 0 (0.0) 1 (8.3)  
   Hispanic 0 (0.0) 1 (8.3)  
   Other 1 (16.7) 0 (0.0)  
Weight (kg) 85.8 ± 21.3 74.5 ± 18.3 0.26 
BMI (kg/m2) 29.1 ± 6.0 26.4 ± 5.4 0.35 
Renal pathology, n (%)    
   ISN/RPS Class III 0 (0.0) 4 (33.3) 0.26 
   ISN/RPS Class IV 4 (66.7) 6 (50.0)  
   ISN/RPS Class V 2 (33.3) 2 (16.7)  
eGFR (mL/min/1.73 m2) 70.4 ± 45.3 86.1 ± 25.0 0.37 
Urine protein (g/24 hours) 2.6 ± 1.9 0.3 ± 0.37 0.02 
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Urine protein/creatinine ratio 155.5 (88.8 – 296.0) 8.0 (6.3 – 24.8) <0.001 
Serum albumin (g/L) 31.5 ± 10.2 39.5 ± 3.3 0.03 
Serum complement (g/L)    
   C3 1.1 ± 0.3 1.0 ± 0.3 0.75 
   C4 0.2 ± 0.2 0.2 ± 0.1 0.43 
Anti–dsDNA 54.5 ± 31.6 33.0 ± 41.8 0.30 
EC–MPS dose (mg/day) 1350.0 (810.0 – 1620.0) 1440.0 (1080.0 – 1440.0) 0.81 
Prednisolone dose (mg/day) 8.8 (4.4 – 23.8) 5.0 (5.0 – 10.0) 0.30 
MPA pharmacokinetic parameters    
Total MPA concentration    
   AUC0-12 (mg·h/L) 49.6 ± 41.7 37.8 ± 18.9 0.32 
   Dose normalised AUC0-12 (mg·h/L/g) 77.8 ± 59.3 82.5 ± 70.7 0.88 
   C0 (mg/L) 1.5 ± 1.1 1.5 ± 0.8 0.92 
   Dose normalised C0 (mg/L/g) 2.5 ± 1.5 3.4 ± 3.0 0.42 
   Cmax (mg/L) 18.2 ± 12.4 13.9 ± 6.4 0.25 
   Dose normalised Cmax (mg/L/g) 28.2 ± 18.7 31.3 ± 30.0 0.80 
   C12 (mg/L) 2.4 ± 2.3 1.8 ± 0.8 0.36 
   Dose normalised C12 (mg/L/g) 3.8 ± 3.2 4.3 ± 4.3 0.81 
Free MPA concentration    
   AUC0-12 (µg·h/L) 631.8 ± 332.8 311.6 ± 143.0 0.01 
   Dose normalised AUC0-12 (µg·h/L/g) 1012.5 ± 383.1 731.9 ± 527.8 0.23 
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   C0 (µg/L) 12.1 (9.9 – 30.0) 10.4 (6.2 – 13.8) 0.44 
   Dose normalised C0 (µg/L/g) 24.2 (14.0 – 41.7)  19.5 (11.9 – 38.6)  0.76 
   Cmax (µg/L) 273.0 ± 189.6 103.4 ± 51.5 0.01 
   Dose normalised Cmax (µg/L/g) 451.7 ± 317.1 252.7 ± 210.8 0.10 
   C12 (µg/L) 29.6 ± 25.0 10.9 ± 5.7 0.02 
   Dose normalised C12 (µg/L/g) 45.3 ± 32.1 28.2 ± 28.9 0.24 
Participants with therapeutic MPA exposure range, n (%)c    
   Overall 3 (33.3) 6 (33.3) 1.00 
   Therapeutic exposure on Visit 1 1 (16.7) 3 (25.0) 1.00 
   Therapeutic exposure on Visit 2 2 (66.7) 3 (50.0) 1.00 
Treatment group, n (%)    
   Fixed–dosing 2 (22.2) 7 (77.8) 0.62 
   Concentration–controlled 4 (44.4) 5 (55.6)  
ALP = alkaline phosphatase; ALT = alanine transaminase; Anti–dsDNA = anti-double strand DNA; ARB = angiotensin II receptor blocker; AST 
= aspartate transaminase; AUC = area under the concentration-time curve; AUC0-12 = area under the concentration-time curve between 0 and 12 
hours; BMI = body mass index; C0 = pre–dose concentration before EC–MPS administration; C12 = trough concentration at 12 hours post-EC–
MPS administration; Cmax = maximal MPA concentration; EC–MPS = enteric–coated mycophenolate sodium; eGFR = estimated glomerular 
filtration rate; GGT = gamma–glutamyl transferase; ISN/RPS = International Society of Nephrology/Renal Pathology Society; MPA = 
mycophenolic acid. 
aData are presented as mean ± standard deviation or median (interquartile range) for continuous variables and number and percentage for 
categorical variables. 
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bContinuous variables were compared using the t–test or Mann–Whitney U–test as appropriate and dichotomous variables were compared using 
the Pearson’s chi–square test or Fisher’s exact test as appropriate. Bold values indicate statistical significance (p<0.05). 
cTarget MPA exposure for participants receiving EC–MPS as induction therapy was 40–60 mg·h/L and 30–50 mg·h/L for maintenance therapy. 
 
 
 
 
 
Table 5: Adverse events 
Summary of adverse events, n (%) Fixed–dosing (n = 9) Concentration–controlled (n = 9) p-value 
Participants with ≥1 adverse event 1 (11.1) 1 (11.1) 1.00 
Participants with adverse event leading to  
EC-MPS cessation 
2 (22.2) 2 (22.2) 1.00 
Total adverse events 5 7 0.32 
   Fever 1 1  
   Infection 0 1  
   Nausea & vomiting 1 1  
   Other 3 4  
 
AC
CE
PT
ED
Copyright © 201 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of
Therapeutic DrugMonitoring and Clinical Toxicology
 9
Figure 1: Study flow chart 
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Figure 2: Correlations between MPA C0 and MPA AUC0-12 for (A) total MPA and 
(B) free MPA concentrations, between MPA Cmax and AUC0-12 for (C) total MPA 
and (D) free MPA concentrations, and between MPA C12 and MPA AUC0-12 for 
(D) total MPA and (E) free MPA concentrations 
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AUC0-12 = area under the concentration-time curve between 0 and 12 hours; C0 = 
pre-dose concentration before EC-MPS administration; Cmax = maximal MPA 
concentration C12 = trough concentration at 12 hours post-EC-MPS administration; 
MPA = mycophenolic acid. 
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Figure 3: Total and free MPA AUC0-12 between fixed-dosing and concentration-
controlled participants across the study visitsa,b 
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AUC0-12 = area under the concentration-time curve between 0 and 12 hours; CC = 
concentration–controlled; FD = fixed–dosing; MPA = mycophenolic acid. 
aMeans with standard deviations are presented. 
bDashed blue circles refer to the target MPA exposure range for patients receiving 
EC–MPS as induction therapy (40–60 mg·h/L) and dashed red lines refer to the 
target MPA exposure range for patients receiving EC–MPS as maintenance therapy 
(30–50 mg·h/L).    
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Figure 4: MPA exposure between fixed-dosing and concentration-controlled 
participants across the study visitsa,b,c 
 
aTarget MPA exposure for participants receiving EC-MPS as induction therapy was 
40-60 mg·h/L and 30-50 mg·h/L for maintenance therapy. 
bSubtherapeutic MPA exposure for participants receiving EC-MPS as induction 
therapy was defined as <40 mg·h/L and <30 mg·h/L for maintenance therapy. 
cSupratherapeutic MPA exposure for participants receiving EC-MPS as induction 
therapy was defined as >60 mg·h/L and >50 mg·h/L for maintenance therapy. 
FD0 = Overall MPA exposure of FD participants; CC0 = Overall MPA exposure of CC 
participants; FD1 = MPA exposure of FD participants on study visit 1; CC1 = MPA 
exposure
 
of FD participants on study visit 1; FD2 = MPA exposure of FD participants 
on study visit 2; CC2 = MPA exposure of CC participants on study visit 2; FD3 = MPA 
exposure
 
of FD participants on study visit 3; CC3 = MPA exposure of CC participants 
on study visit 3. 
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Figure 5: Changes in treatment-related variables over the 48-week of study perioda 
CC = concentration controlled; FD = fixed-dosing; eGFR =estimated glomerular filtration rate 
aNo significant differences were observed in; (A) serum creatinine (p= 0.33), (B) blood urea (p = 0.17), (C) estimated glomerular 
filtration rate (p = 0.95), (D) serum albumin (p = 0.68), (E) serum C3 (p = 0.35), and (F) serum C4 (p = 0.63) between FD and CC 
participants throughout the study period.  
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